Form 8-K - Current report:
SEC Accession No. 0000950170-23-060230
Filing Date
2023-11-07
Accepted
2023-11-07 16:05:18
Documents
14
Period of Report
2023-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mnkd-20231107.htm   iXBRL 8-K 44472
2 EX-99.1 mnkd-ex99_1.htm EX-99.1 615670
3 GRAPHIC img208524907_0.jpg GRAPHIC 8836
  Complete submission text file 0000950170-23-060230.txt   813851

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mnkd-20231107_lab.xml EX-101.LAB 13474
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mnkd-20231107_pre.xml EX-101.PRE 9908
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mnkd-20231107.xsd EX-101.SCH 2481
8 EXTRACTED XBRL INSTANCE DOCUMENT mnkd-20231107_htm.xml XML 4733
Mailing Address 1 CASPER STREET DANBURY CT 06810
Business Address 1 CASPER STREET DANBURY CT 06810 818-661-5000
MANNKIND CORP (Filer) CIK: 0000899460 (see all company filings)

EIN.: 133607736 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50865 | Film No.: 231383630
SIC: 2834 Pharmaceutical Preparations